Our experience was that most doublet regimen are well tolerated in the elderly, and this echoed the finding in the IFCT-0501 trial in which patients aged at least 70 years were randomized to receive either vinorelbine or gemcitabine alone or with monthly carboplatin combined with weekly paclitaxel demonstrated that there was a highly significant benefit of survival in the doublet chemotherapy arm [ 30 ].
← all excerpts
Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.
1
—
—